Browse CIDEC

Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Endoplasmic reticulum. Lipid droplet. Note=Diffuses quickly on lipid droplet surface, but becomes trapped and clustered at lipid droplet contact sites, thereby enabling its rapid enrichment at lipid droplet contact sites.
Domain PF02017 CIDE-N domain
Function

Binds to lipid droplets and regulates their enlargement, thereby restricting lipolysis and favoring storage. At focal contact sites between lipid droplets, promotes directional net neutral lipid transfer from the smaller to larger lipid droplets. The transfer direction may be driven by the internal pressure difference between the contacting lipid droplet pair. Its role in neutral lipid transfer and lipid droplet enlargement is activated by the interaction with PLIN1. May act as a CEBPB coactivator in the white adipose tissue to control the expression of a subset of CEBPB downstream target genes, including SOCS1, SOCS3, TGFB1, TGFBR1, ID2 and XDH. When overexpressed in preadipocytes, induces apoptosis or increases cell susceptibility to apoptosis induced by serum deprivation or TGFB treatment. As mature adipocytes, that express high CIDEC levels, are quite resistant to apoptotic stimuli, the physiological significance of its role in apoptosis is unclear. May play a role in the modulation of the response to osmotic stress by preventing NFAT5 to translocate into the nucleus and activate its target genes expression.

> Gene Ontology
 
Biological Process GO:0034389 lipid particle organization
GO:0097194 execution phase of apoptosis
Molecular Function -
Cellular Component GO:0005811 lipid particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-174800: Chylomicron-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CIDEC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CIDEC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CIDEC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4440.439
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8170.373
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1530.843
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.0430.0221
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.7150.0359
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2010.429
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.9980.347
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7350.627
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.7450.0945
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.1850.0543
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 284.8219.33e-05
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1560.6
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CIDEC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CIDEC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CIDEC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CIDEC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CIDEC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CIDEC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CIDEC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCIDEC
Namecell death-inducing DFFA-like effector c
Aliases CIDE-3; FLJ20871; Fsp27; CIDE3; FPLD5; fat specific protein 27; Fat-specific protein FSP27 homolog; Cell dea ......
Chromosomal Location3p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CIDEC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.